Browse hierarchy: [Gastroenterology, Urology (GU)](/submissions/GU) → [Subpart F — Therapeutic Devices](/submissions/GU/subpart-f%E2%80%94therapeutic-devices) → [21 CFR 876.5982](/submissions/GU/subpart-f%E2%80%94therapeutic-devices/876.5982) → QFQ — Ingested, Transient, Space Occupying Device For Weight Management And/Or Weight Loss

# QFQ · Ingested, Transient, Space Occupying Device For Weight Management And/Or Weight Loss

_Gastroenterology, Urology · 21 CFR 876.5982 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QFQ

## Overview

- **Product Code:** QFQ
- **Device Name:** Ingested, Transient, Space Occupying Device For Weight Management And/Or Weight Loss
- **Regulation:** [21 CFR 876.5982](/submissions/GU/subpart-f%E2%80%94therapeutic-devices/876.5982)
- **Device Class:** 2
- **Review Panel:** [Gastroenterology, Urology](/submissions/GU)

## Identification

This device is an ingested material that transiently occupies space in the stomach. The device passes from the body via the natural gastrointestinal tract.

## Classification Rationale

Class II (special controls). The special controls for this device are:

## Special Controls

In combination with the general controls of the FD&C Act, the ingested, transient, space occupying device for weight management and/or weight loss is subject to the following special controls:

*Classification.* Class II (special controls). The special controls for this device are:(1) The patient-contacting components of the device must be demonstrated to be biocompatible for its intended use.
(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions for use, as follows:
(i) Performance bench testing in a simulated use model must evaluate device disintegration and device hydration state throughout the gastrointestinal tract;
(ii) Bioburden and moisture content assessments must evaluate device infection risk throughout the labeled shelf life; and
(iii) Performance data must support the shelf life of the device by demonstrating continued package integrity and device functionality over the labeled shelf life.
(3) Clinical performance testing must demonstrate the device performs as intended and evaluate the following:
(i) Weight change;
(ii) All adverse events, including obstruction, dilation, diarrhea, constipation, and dehydration; and
(iii) Interaction with representative medications.
(4) Physician and patient device labeling must state:
(i) The clinical benefit of the device as assessed by using percent total body weight loss;
(ii) Treatment must be offered in combination with diet and exercise;
(iii) Instructions on how to use the device as intended including how to avoid interaction with medication; and
(iv) The shelf life of the device.

## Recent Cleared Devices (3 of 3)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K240544](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QFQ/K240544.md) | Epitomee | Epitomee Medical , Ltd. | Sep 13, 2024 | SESE |
| [K230133](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QFQ/K230133.md) | Plenity | Gelesis, Inc. | Jan 19, 2024 | SESE |
| [DEN180060](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QFQ/DEN180060.md) | Plenity | Gelesis, Inc. | Apr 12, 2019 | DENG |

## Top Applicants

- Gelesis, Inc. — 2 clearances
- Epitomee Medical , Ltd. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QFQ](https://fda.innolitics.com/submissions/GU/subpart-f%E2%80%94therapeutic-devices/QFQ)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com